Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Adjuvant Abemaciclib Plus Endocrine Therapy Sustains iDFS, DRFS Benefit in HR+, HER2– Early Breast Cancer

October 20th 2023

Adjuvant treatment with the combination of abemaciclib and endocrine therapy (ET) maintained a benefit in invasive disease-free survival and distant relapse–free survival compared with ET alone in patients with hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer.

Approaches to Sequencing Therapies for HER2+ mBC

October 20th 2023

Jane Meisel, MD, describes a personalized approach to later lines of treatment for HER2+ metastatic breast cancer, explaining the importance of considering patient priorities and individual circumstances.

The Role of Trastuzumab Deruxtecan in the Treatment of HER2+ mBC

October 20th 2023

Jane Meisel, MD, elaborates on the evolution and significance of the antibody-drug conjugate trastuzumab deruxtecan in treating HER2+ metastatic breast cancer, highlighting its effectiveness and considerations for its usage.

Toxicity Management for T-DM1 and T-DXd in Breast Cancer

October 20th 2023

Specialists in breast cancer review toxicity management practices for T-DM1 and trastuzumab deruxtecan [T-DXd].

Antibody-Drug Conjugates in Breast Cancer

October 20th 2023

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research.

ESMO 2023: Experts Preview Anticipated Data Spanning Tumor Types

October 19th 2023

The 2023 ESMO Congress, which is taking place in Madrid, Spain, and will continue to be accessible online via a virtual platform, is gearing up to kick off, and the oncology community is ready to learn more about the latest data across malignancies.

Dr Esteva on the monarchE and NATALEE Trials in HR+/HER2– Breast Cancer

October 17th 2023

Francisco J. Esteva, MD, PhD, discusses the phase 3 monarchE and NATALEE trials in patients with hormone receptor–positive/HER2-negative breast cancer.

Emerging Therapies Underscore Need for Genomic Testing in HR+/HER2– Breast Cancer

October 16th 2023

Kari Wisinski, MD, highlights the use of oral selective estrogen receptor degraders and CDK4/6 inhibitors in the treatment of patients with hormone receptor–positive/HER2-negative breast cancer, the growing role of antibody-drug conjugates across the breast cancer spectrum, and ongoing research taking place at Carbone Cancer Center.

Best Practices for Patient Education Surrounding Cancer Treatment

October 13th 2023

The expert panel has a comprehensive discussion about best practices for patient education and the barriers to effective testing.

Molecular Testing Considerations in Cancer Treatment

October 13th 2023

Medical oncologists review the complexities of molecular testing, including tissue exhaustion, and discuss management approaches.

Current Standard of Care for HER2+ Metastatic Breast Cancer (mBC)

October 13th 2023

Jane Meisel, MD, details the current standard-of-care for HER2+ metastatic breast cancer in the US, emphasizing personalized care and the importance of shared decision-making with patients.

Evolution of Advanced HER2+ Breast Cancer Management

October 13th 2023

Jane Meisel, MD, highlights how recent advancements in HER2+ advanced breast cancer treatments such as the introduction of tucatinib and trastuzumab deruxtecan are transforming patient care, particularly for those with brain metastases.

Dr Krill-Jackson on the Practice-Changing Effect of T-DXd in HER2+ Breast Cancer

October 12th 2023

Elisa Krill-Jackson, MD, highlights the practice-changing effects of fam-trastuzumab deruxtecan-nxki in metastatic, HER2-positive breast cancer, as well as whether there is still a role for trastuzumab emtansine in this setting.

Dr Vikas on the Benefit of Utilizing MRD Detection in Breast Cancer Treatment

October 12th 2023

Praveen Vikas, MBBS, discusses the benefits associated with utilizing minimal residual disease detection in breast cancer.

Let’s Talk About Post-Mastectomy Chest Numbness

October 11th 2023

Just as advances in surgical techniques have made it possible to treat breast cancer and offer numerous options for breast reconstruction, there is also a surgical advancement to address a functional impairment often unintentionally caused by mastectomy: chest numbness.

Advice For Providers Caring for Patients With HR+/HER2- mBC

October 10th 2023

Virginia Kaklamani, MD, and Elizabeth Diaz, PA-C, share advice for providers managing patients with HR+/HER2- metastatic breast cancer.

Remaining Unmet Needs for Patients With HR+/HER2- mBC

October 10th 2023

Experts highlight some remaining unmet needs in the treatment and management of patients with HR+/HER2- metastatic breast cancer.

Dr McLellan on the Association Between A Skin Bacterium and Severe Acute Radiation Dermatitis

October 9th 2023

Beth N. McLellan, MD, discusses the use of a low-cost, topical treatment to prevent severe cases of acute radiation dermatitis potentially caused by the skin bacterium Staphylococcus aureus in breast cancer.

Dr Haffty on the Rationale for Investigating Preoperative Radiation Boosts in Breast Cancer

October 7th 2023

Bruce Haffty, MD, MS, discusses the rationale for launching a clinical trial to assess the feasibility of preoperative radiation boost in patients with breast cancer.

Biomarker Testing in Gastrointestinal and Lung Cancers

October 6th 2023

Comprehensive insights on biomarker testing practices for patients with lung or gastrointestinal cancers.